Lyra Therapeutics Inc.
LYRA | NASDAQ
$0.49
-$0.83 (-62.88%)
At close: Mar 16, 2026, 4:00 PM ET
Market Data
Market Cap $2.34M
Enterprise Value N/A
Beta 0.06
Average Volume N/A
Shares Outstanding (Diluted) 1.77M
Shares Change YoY N/A
Institutional Ownership N/A
Exchange NASDAQ
ISIN N/A
Valuation
PE Ratio -0.14
Forward PE N/A
PEG Ratio 0.00
Forward PEG N/A
PS Ratio 3.90
Forward PS N/A
PB Ratio -0.54
P/FCF Ratio N/A
P/Adj. FCF Ratio N/A
P/OCF Ratio N/A
EV/Sales 19.44
EV/EBIT N/A
EV/EBITDA -0.38
EV/FCF N/A
Earnings Yield N/A
FCF Yield -1612.8%
Adj. FCF Yield N/A
Financial Health
Net Debt $9.32M
Total Debt N/A
Cash & Short-Term Investments N/A
Total Assets N/A
Current Ratio 2.43
Quick Ratio N/A
Debt / Equity Ratio N/A
Debt / EBITDA N/A
Debt / FCF N/A
OCF / Debt N/A
Interest Coverage 0.00
Altman Z-Score N/A
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 50.0%
Operating Profit Margin -5822.5%
EBITDA Margin N/A
Net Profit Margin -5491.2%
FCF Margin -6297.5%
Adj. FCF Margin N/A
SBC / Revenue N/A
SBC Impact (per share) -10.8%
Returns
Return on Assets -75.4%
Return on Equity -1032.8%
Return on Invested Capital -89.8%
Return on Capital Employed N/A
Return on Tangible Assets N/A
Historical Growth (CAGR)
Revenue CAGR 3Y 75.3%
Revenue CAGR 5Y N/A
Revenue CAGR 10Y N/A
EPS CAGR 3Y 19.1%
EPS CAGR 5Y 19.5%
EPS CAGR 10Y N/A
FCF CAGR 3Y -49.2%
FCF CAGR 5Y -83.6%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Hold
Analyst Count N/A
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $0.50
Price Target Upside N/A
Income Statement
Revenue $600K
Gross Profit N/A
Operating Income N/A
EBITDA N/A
Net Income $-32.95M
EPS (Diluted) -$9.19
Revenue / Employee $20K
Profit / Employee $-1.1M
Employees N/A
Add to Watchlist
Select watchlists to add or remove LYRA